Iberdomide Maintenance Therapy in Patients With Multiple Myeloma

Study Number

3440822

Phase

Age Group

Adult

Principal Investigator

Purpose

This study will determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-autologous stem cell transplant (ASCT). Treatment will continue until disease progression or toxicity. The results from this study will inform the feasibility of pursuing a study comparing iberdomide to lenalidomide maintenance post-ASCT.

Check your eligibility for this trial

Check now

Full Title

Phase 2 study of iberdomide maintenance therapy following autologous stem cell transplant in patients with multiple myeloma

ClinicalTrials.Gov ID

NCT05177536

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.